Citigroup
INO icon

Citigroup’s Inovio Pharmaceuticals INO Stock Holding History

Citigroup’s Portfolio INO Stock Details INO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-8,200
Closed -$871K – 6806
2020
Q4 		$871K Sell
8,200
-7,475
-48% -$995K ﹤0.01% 3675
2020
Q3 		$2.18M Buy
15,675
+5,692
+57% +$1.19M ﹤0.01% 2574
2020
Q2 		$3.23M Sell
9,983
-1,692
-14% -$272K ﹤0.01% 2285
2020
Q1 		$1.04M Buy
11,675
+10,758
+1,173% +$663K ﹤0.01% 3130
2019
Q4 		$36K Buy
917
+809
+749% +$24.3K ﹤0.01% 6582
2019
Q3 		$3K Sell
108
-267
-71% -$8.12K ﹤0.01% 7458
2019
Q2 		$13K Sell
375
-183
-33% -$7.27K ﹤0.01% 7227
2019
Q1 		$25K Sell
558
-1,525
-73% -$76.9K ﹤0.01% 6837
2018
Q4 		$100K Sell
2,083
-75
-3% -$4.56K ﹤0.01% 5648
2018
Q3 		$144K Buy
2,158
+341
+19% +$19K ﹤0.01% 5549
2018
Q2 		$85K Buy
1,817
+992
+120% +$54.7K ﹤0.01% 5858
2018
Q1 		$47K Sell
825
-1,467
-64% -$79.4K ﹤0.01% 6210
2017
Q4 		$114K Buy
2,292
+625
+37% +$38.7K ﹤0.01% 5524
2017
Q3 		$127K Sell
1,667
-2,183
-57% -$162K ﹤0.01% 5367
2017
Q2 		$362K Buy
3,850
+1,950
+103% +$167K ﹤0.01% 4296
2017
Q1 		$151K Buy
1,900
+417
+28% +$33.2K ﹤0.01% 4891
2016
Q4 		$124K Buy
1,483
+200
+16% +$18.1K ﹤0.01% 5640
2016
Q3 		$144K Sell
1,283
-225
-15% -$24.9K ﹤0.01% 4929
2016
Q2 		$167K Buy
1,508
+1,333
+762% +$162K ﹤0.01% 4660
2016
Q1 		$18K Buy
+175
New +$13.5K ﹤0.01% 6593

Other funds holding INO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citigroup's INO Position: Q4 2025 in Review

Citigroup sold out of Inovio Pharmaceuticals (INO) in Q4 2025, closing a stake of 12,977 shares — an estimated $30.4K sold.

Citigroup first reported a position in INO in Q2 2013 and held it in 50 quarters. The position peaked at $7.39M in Q2 2020. 102 funds tracked by Wall St. Rank hold INO as of Q4 2025.

  • Citigroup reported no remaining Inovio Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Citigroup sold 12,977 Inovio Pharmaceuticals shares in Q4 2025, an estimated $30.4K.
  • Citigroup first reported a position in Inovio Pharmaceuticals in Q2 2013 and held it in 50 quarters.
  • Citigroup's Inovio Pharmaceuticals position peaked at $7.39M in Q2 2020.
  • 102 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q4 2025.

Based on Citigroup's 13F filing for Q4 2025, filed 13 Feb 2026.